Acute Bronchiolitis and Severity Markers: Interest in Protein CC16 (CC16)
Acute bronchiolitis is a common viral infection in infants mainly due to RSV and rhinovirus.
Biomarkers can be useful for predicting its severity. The serum CC16 is a marker of epithelial aggression. Its rate increase during RSV bronchiolitis in infants less than 7 months. It could be an early predictive biomarker of the severity of acute bronchiolitis, and secondarily for the development of asthma.
Two other markers of airway aggression seem to increase during acute bronchiolitis: serum SP-D protein and serum soluble receptor sRAGE.
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Acute Bronchiolitis and Severity Markers: Interest in Protein CC16|
- Serum CC16 rate [ Time Frame: at day 1 ]
- Urinary CC16 rate [ Time Frame: at day 1 ]
- SP-D rates [ Time Frame: at day 1 ]
- sRAGE rates [ Time Frame: at day 1 ]
|Study Start Date:||November 2015|
|Estimated Study Completion Date:||January 2019|
|Estimated Primary Completion Date:||August 2018 (Final data collection date for primary outcome measure)|
Experimental: acute bronchiolitis
Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system
|Drug: Protein CC16|
Please refer to this study by its ClinicalTrials.gov identifier: NCT02984046
|Contact: Patrick LACARINemail@example.com|
|Clermont-Ferrand, France, 63003|
|Contact: Patrick LACARIN 0473751195 firstname.lastname@example.org|
|Principal Investigator: André LABBE|
|Principal Investigator:||André LABBE||University Hospital, Clermont-Ferrand|